Table 4. Summary of the relative potencies of the shuffled IFN-α and control compounds in the WISH EMCV antiviral assay

Sample[†]	Log mean EC50	SD	n	Mean EC$_{50}$, ng/ml	Fold over IFN-α2b[‡]	Fold over IFN-con1[‡]	P value sample vs. IFN-con1
B9X23 *	-2.30	0.340	9	0.00504	42	14	0.00155
B9X25 *	-2.06	0.307	9	0.00871	24	8	0.00578
B9X1.2 *	-2.04	0.227	7	0.00911	23	7.9	0.00682
B9X16 *	-2.00	0.224	8	0.00992	21	7.3	0.00843
B9X28 *	-1.98	0.179	9	0.0104	20	7.0	0.00990
B9X22 *	-1.98	0.499	8	0.0104	20	6.9	0.0121
B9X27 *	-1.94	0.244	8	0.0115	18	6.3	0.0119
B9X14 *	-1.91	0.240	9	0.0122	17	5.9	0.0136
B9X24 *	-1.90	0.329	8	0.0125	17	5.8	0.0147
B9X26 *	-1.87	0.247	7	0.0135	16	5.4	0.0176
B9X18 *	-1.76	0.240	7	0.0175	12	4.1	0.0345
B9X17 *	-1.72	0.217	7	0.0191	11	3.8	0.0431
B9X1.1	-1.60	0.044	7	0.0253	8.3	2.8	0.0882
B9X15	-1.39	0.110	8	0.0412	5.1	1.8	0.313
B9X12	-1.23	0.232	8	0.0595	3.5	1.2	0.727
IFN-con1	-1.14	0.527	6	0.0722	2.9	1.0	-
IFN-α2b	-0.677	0.334	6	0.210	1.0	0.34	0.103
IFN-α2a	-0.515	0.609	8	0.305	0.69	0.24	0.0627

The samples are listed in order of decreasing antiviral potency. The dash indicates not applicable.

[†]The mean Log EC$_{50}$ values of those interferon samples marked with an asterisk are statistically different from the mean log EC$_{50}$ value of IFN-con1 in the WISH EMCV assay based on a two-sample t test with unequal variance.

[‡]Fold improvements were calculated as a ratio of mean EC$_{50}$ (ng/ml) values relative to IFN-α2b and IFN-con1.